Stock PCSA PROCESSA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Processa Pharmaceuticals, Inc.

Equities

PCSA

US74275C3043

Real-time Estimate Cboe BZX
Other stock markets
 14:33:07 08/05/2024 BST 		5-day change 1st Jan Change
2.455 USD -1.01% Intraday chart for Processa Pharmaceuticals, Inc. +13.76% -62.94%
04-30 Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research CI
04-30 Certain Common Warrants of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024. CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
AQ
Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
AQ
Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial
AQ
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
AQ
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
AQ
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
AQ
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
AQ
Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
AQ
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering
AQ
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
AQ
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
GL
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses
AQ
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
AQ
Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split
AQ
Processa Pharmaceuticals to Present at the Biotech Showcase 2024
AQ
Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
AQ
Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine
AQ
Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference
AQ
Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook
AQ
Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PCSA Stock
  4. News Processa Pharmaceuticals, Inc.
  5. Press Releases